Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 501 - 525 of 14724 in total

Givosiran

Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States ... [A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [ ... represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Collagenase clostridium histolyticum

Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers. On July 6,...
Approved
Investigational
Matched Description: … [L14872] Also known as Qwo, this injection is the first approved injectable treatment for cellulite and ... It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and ... [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA …
Matched Categories: … Enzymes and Coenzymes ... Skin and Mucous Membrane Agents ... Preparations for Treatment of Wounds and Ulcers …

Propofol

Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness,...
Approved
Investigational
Vet approved
Matched Description: … Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia ... for induction and/or maintenance of anaesthesia prior to and during surgeries. ... effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. …
Matched Categories: … Hypnotics and Sedatives …

Sodium carbonate

Sodium Carbonate is the disodium salt of carbonic acid with alkalinizing property. When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. As a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid.
Approved
Matched Description: … When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. …

Peginterferon beta-1a

Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of...
Approved
Matched Description: … It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular ... [L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ... , disrupting communication between the brain and other parts of the body. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Flosequinan

Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Approved
Withdrawn
Matched Description: … Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due …

Bumadizone

Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis and gout . Its use is restricted to these conditions, due to risks this drug poses .
Approved
Matched Description: … Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic ... , and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis and gout …
Matched Categories: … Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Pramipexole

Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is...
Approved
Investigational
Matched Description: … It was first approved by the FDA in 1997 [L5882]. ... agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and ... Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of …

Hexachlorophene

A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)
Approved
Withdrawn
Matched Description: … It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders …
Matched Categories: … Phenol and Derivatives ... Antiseptics and Disinfectants …

Daridorexant

Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. ... [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ. ... [L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant]. …
Matched Categories: … Hypnotics and Sedatives …

Troglitazone

Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Description: … It was superseded by [pioglitazone] and [rosiglitazone]. …
Matched Categories: … Alimentary Tract and Metabolism …

Esmolol

Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased...
Approved
Withdrawn
Matched Description: … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate ... Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. …

Ubrogepant

Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... [A189207] Ubrogepant was approved by Health Canada on November 10, 2022. ... peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. …

Finafloxacin

Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.
Approved
Investigational
Matched Description: … Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December ... the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and …

Cinoxacin

Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Approved
Investigational
Withdrawn
Matched Description: … Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections …

Imipenem

Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.[label] It is stable to many beta-lactamases. Similar compounds include meropenem, known for having greater activity against Gram negative bacteria, and the newer ertapenem which exhibits...
Approved
Matched Description: … product with cilastatin and [relebactam] which was recently approved by the FDA. ... Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed ... gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. …
Matched Mixtures name: … Imipenem and Cilastatin ... Imipenem and Cilastatin ... Imipenem and Cilastatin …
Matched Categories: … imipenem and cilastatin ... imipenem, cilastatin and relebactam …

Taliglucerase alfa

Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Matched Description: … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Lynestrenol

Lynestrenol is a progestin and prodrug of norethisterone.
Approved
Investigational
Matched Description: … Lynestrenol is a progestin and prodrug of [norethisterone]. …
Matched Categories: … lynestrenol and estrogen ... lynestrenol and estrogen ... lynestrenol and ethinylestradiol ... lynestrenol and ethinylestradiol ... Genito Urinary System and Sex Hormones …

Ursodeoxycholic acid

Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool.[A256272,A256277] UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years.[A256267,A256463] UDCA was first characterized...
Approved
Investigational
Matched Description: … [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary ... [A256267,A256463] UDCA was first characterized in the bile of the Chinese black bear and is formed by …
Matched Categories: … Bile Acids and Salts ... Bile and Liver Therapy ... Bile acids and derivatives ... Alimentary Tract and Metabolism ... Cholagogues and Choleretics …

Penicillamine

Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Penicillamine and Similar Agents ... Antiinflammatory and Antirheumatic Products …

Oxolamine

Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant . It is listed as a prescription drug in New Zealand legislation . Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation .
Approved
Matched Description: … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422]. ... Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant …
Matched Categories: … Cough and Cold Preparations …

Tivozanib

Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Description: … It was approved on March 10, 2021 by the FDA. ... Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … Linagliptin was approved by the FDA on May 2, 2011[L9557]. ... that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Budesonide

Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Description: … of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions …
Matched Mixtures name: … Budesonide and Formoterol Fumarate Dihydrate ... Budesonide and Formoterol Fumarate Dihydrate ... Budesonide and Formoterol Fumarate Dihydrate …
Matched Categories: … Corticosteroids, Potent (Group III) ... Alimentary Tract and Metabolism ... salbutamol and budesonide ... formoterol and budesonide ... salmeterol and budesonide …

Masoprocol

A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
Approved
Investigational
Matched Description: … It also serves as an antioxidant in fats and oils. [PubChem] ... The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 501 - 525 of 14724 in total